Beta Bionics, Inc. (BBNX) Income Statement
BBNX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBBNX revenue and net income
Where BBNX's revenue goes
2025Each bar shows an amount and its share of revenue. BBNX kept −73.0% of revenue as net income.
BBNX profit margins
BBNX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +53.9% | +724.3% | — | — |
| Gross profit | +54.8% | +577.0% | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BBNX quarterly EPS vs estimates
Beta Bionics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: October 27, 2026 (estimate $-0.53).
BBNX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $100.3M | $65.1M | $12.0M | $179,000 |
| Cost of revenue | $44.7M | $29.2M | $5.7M | $0 |
| Gross profit | $55.5M | $35.9M | $6.3M | $179,000 |
| Research & development | $34.8M | $26.2M | $17.9M | $31.4M |
| Sales, general & admin | $92.4M | $55.0M | $24.2M | $33.5M |
| Total operating expenses | $127.2M | $81.1M | $42.2M | $66.0M |
| Operating income | −$71.7M | −$45.3M | −$35.9M | −$65.8M |
| Interest income | $10.9M | $3.9M | $1.8M | $196,000 |
| Interest expense | — | — | $68,000 | $14,000 |
| Income before taxes | −$73.2M | −$54.8M | −$44.1M | −$64.8M |
| Income taxes | $1,000 | — | — | — |
| Net income | −$73.2M | −$54.8M | −$44.1M | −$64.8M |
| EBITDA | −$70.3M | −$52.5M | −$42.0M | −$62.7M |
| EPS (diluted) | −$1.83 | −$3.54 | −$1.03 | — |
| Gross margin | 55.4% | 55.1% | 52.6% | 100.0% |
| Operating margin | −71.5% | −69.5% | −298.9% | −36,784.4% |
| Net margin | −73.0% | −84.1% | −367.6% | −36,173.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0M | $27.6M | $32.1M | $27.3M | $23.2M | $17.6M | $20.4M | $16.7M | $15.0M | $12.9M | $8.3M | $3.1M |
| Cost of revenue | $13.1M | $11.2M | $13.2M | $12.1M | $10.7M | $8.7M | $8.8M | $7.8M | $7.0M | $5.7M | $3.3M | $1.9M |
| Gross profit | $18.9M | $16.4M | $18.9M | $15.1M | $12.5M | $9.0M | $11.7M | $8.9M | $8.1M | $7.2M | $5.1M | $1.2M |
| Research & development | $10.2M | $10.4M | $10.1M | $8.2M | $8.9M | $7.6M | $9.2M | $5.1M | $6.3M | $5.5M | $4.5M | $3.9M |
| Sales, general & admin | $34.2M | $30.4M | $24.9M | $24.0M | $23.5M | $20.0M | $15.5M | $14.8M | $13.5M | $11.2M | $9.0M | $6.2M |
| Total operating expenses | $44.5M | $40.7M | $35.1M | $32.2M | $32.4M | $27.6M | $24.7M | $19.9M | $19.9M | $16.7M | $13.4M | $10.0M |
| Operating income | −$25.6M | −$24.3M | −$16.1M | −$17.0M | −$19.9M | −$18.6M | −$13.0M | −$11.0M | −$11.8M | −$9.5M | −$8.4M | −$8.8M |
| Interest income | $2.2M | $2.4M | $2.7M | $2.8M | $3.0M | $2.4M | $951,000 | $826,000 | $993,000 | $1.1M | $1.3M | — |
| Interest expense | — | — | — | — | — | — | $2,000 | — | — | — | $55,000 | — |
| Income before taxes | −$23.4M | −$21.9M | −$13.5M | −$14.2M | −$16.9M | −$28.7M | −$18.1M | −$9.7M | −$14.5M | −$12.4M | −$18.8M | −$8.7M |
| Income taxes | — | — | $1,000 | — | — | — | — | — | — | — | — | — |
| Net income | −$23.4M | −$21.9M | −$13.5M | −$14.2M | −$16.9M | −$28.7M | −$18.1M | −$9.7M | −$14.5M | −$12.4M | −$18.8M | −$8.7M |
| EBITDA | −$24.5M | −$20.9M | −$12.5M | −$13.5M | −$16.2M | −$28.1M | −$17.6M | −$9.4M | −$13.9M | −$11.9M | −$18.6M | −$8.4M |
| EPS (diluted) | −$0.53 | −$0.36 | −$0.30 | −$0.33 | −$0.27 | −$0.93 | −$2.72 | −$0.82 | — | — | — | — |
| Gross margin | 59.0% | 59.5% | 59.0% | 55.5% | 53.8% | 50.9% | 57.2% | 53.4% | 53.7% | 55.7% | 60.6% | 39.6% |
| Operating margin | −79.9% | −87.9% | −50.2% | −62.5% | −85.5% | −105.7% | −63.8% | −65.7% | −78.3% | −73.1% | −100.2% | −283.9% |
| Net margin | −73.1% | −79.3% | −41.9% | −52.1% | −72.6% | −162.5% | −88.6% | −58.3% | −96.1% | −96.3% | −225.7% | −280.6% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BBNX's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BBNX financial results
In fiscal year 2025 (ended December 31, 2025), Beta Bionics reported revenue of $100.3 million, up 53.9% from the year before. It had a net loss of $73.2 million, a net profit margin of −73.0%. Diluted earnings per share came to −$1.83.
See the BBNX stock overview for the latest quote and news, or the BBNX chart for price history and technical indicators.
BBNX income statement FAQ
What is Beta Bionics's annual revenue?
Beta Bionics reported total revenue of $100.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 53.9% from $65.1 million the previous year.
Is Beta Bionics profitable?
No. Beta Bionics reported a net loss of $73.2 million in fiscal 2025, a net profit margin of −73.0%; its operating margin was −71.5%.
What is Beta Bionics's gross margin?
Beta Bionics's gross margin was 55.4% in fiscal 2025: for every $100 of revenue, Beta Bionics kept $55 after the direct cost of its products and services.
How much does Beta Bionics spend on research and development?
Beta Bionics spent $34.8 million on research and development in fiscal 2025, 34.7% of revenue.
What are Beta Bionics's earnings per share?
Beta Bionics earned $-1.83 per diluted share in fiscal 2025, compared with $-3.54 a year earlier.
When will Beta Bionics report its next earnings?
Beta Bionics is expected to report results for the quarter ending September 30, 2026 on October 27, 2026 after the market closes.
When does Beta Bionics's fiscal year end?
Beta Bionics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.